Numinus Wellness Inc. (TSX: NUMI / OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce Cedar Clinical Research (CCR) is a top research site for MindMed’s Phase 2b study evaluating MM-120 (lysergide D-tartrate) for General Anxiety Disorder. 

CCR’s research clinic in Draper, Utah, is the top enrolling site for the research study – having enrolled and dosed 19 clinical trial participants for the study to date. CCR also recently began enrolling volunteers for this trial at a second research clinic – in Murray, Utah.

“We’re excited to support MindMed in their clinical trial work, by evaluating new important treatments and protocols to address mental health disorders. The fact that our Draper research clinic is the top enrolling site for the study underscores the quality of our clinical research capabilities and recruiting efforts.”

Paul Thielking, Chief Science Officer, Numinus, and Principal Investigator at CCR Murray.

The MindMed study aims to enroll up to 200 participants who will receive a single administration of 25 µg, 50 µg, 100 µg or 200 µg of MM-120 or placebo. Topline results are expected to be announced by MindMed in late 2023.

To learn more about the study, and find out if you qualify to participate in it, please visit: https://www.anxietyresearchstudy.com/

About Numinus

Numinus Wellness Inc. helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.